Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 15,090 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) CEO James F. Oliviero III sold 15,090 shares of Checkpoint Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $4.04, for a total value of $60,963.60. Following the sale, the chief executive officer now directly owns 3,759,929 shares of the company's stock, valued at $15,190,113.16. This trade represents a 0.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Checkpoint Therapeutics Stock Up 0.4 %

Shares of NASDAQ CKPT traded up $0.02 during midday trading on Tuesday, hitting $4.01. The stock had a trading volume of 454,812 shares, compared to its average volume of 1,154,741. The company has a fifty day moving average price of $3.44 and a 200 day moving average price of $3.34. The company has a market capitalization of $335.47 million, a price-to-earnings ratio of -2.18 and a beta of 1.21. Checkpoint Therapeutics, Inc. has a 1-year low of $1.38 and a 1-year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.47). The firm had revenue of $0.04 million for the quarter. On average, research analysts forecast that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Lake Street Capital reissued a "hold" rating and set a $4.10 price target (down previously from $7.00) on shares of Checkpoint Therapeutics in a research report on Monday, March 10th. D. Boral Capital reissued a "buy" rating and set a $4.80 price target on shares of Checkpoint Therapeutics in a research note on Monday, March 31st. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $4.10 price objective on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th.

Institutional Trading of Checkpoint Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CKPT. SBI Securities Co. Ltd. bought a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at about $32,000. State Street Corp raised its position in shares of Checkpoint Therapeutics by 32.2% during the 3rd quarter. State Street Corp now owns 94,424 shares of the company's stock worth $212,000 after purchasing an additional 23,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company's stock worth $958,000 after purchasing an additional 124,787 shares during the last quarter. Virtu Financial LLC boosted its position in Checkpoint Therapeutics by 180.5% during the 4th quarter. Virtu Financial LLC now owns 38,157 shares of the company's stock valued at $122,000 after purchasing an additional 24,552 shares during the period. Finally, Walleye Capital LLC bought a new position in Checkpoint Therapeutics during the 3rd quarter worth $148,000. 22.00% of the stock is owned by institutional investors and hedge funds.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.